Guarneri Fabrizio, Guarneri Claudio, Guarneri Biagio
Institute of Dermatology, University of Messina, Messina, Italy.
Recent Pat Inflamm Allergy Drug Discov. 2007 Nov;1(3):193-217. doi: 10.2174/187221307782418919.
Psoriasis is a cutaneous inflammatory disease, which affects 1-5% of general population and can have, particularly in its moderate-severe forms, a significant impact on the quality of life of patients. Although the etiopathogenesis of psoriasis is not yet fully understood, it has been demonstrated that the disease is the result of a complex interaction of genetic, endogenous and environmental factors, where the immune system has a pivotal role. For this reason, the immune system is the main target of many treatments for psoriasis. The most recent evolution in this field are the so-called biologic agents, custom-designed biomolecules obtained by bioengineering. This review summarizes the currently available data about efficacy, safety and undesired effects of five patented biologics officially approved for the treatment of moderate-to-severe psoriasis: adalimumab, alefacept, efalizumab, etanercept and infliximab. Some patent applications concerning possible future evolutions of the above biologics are also discussed.
银屑病是一种皮肤炎症性疾病，影响着1%至5%的普通人群，尤其是中度至重度形式的银屑病，会对患者的生活质量产生重大影响。尽管银屑病的发病机制尚未完全明确，但已证实该疾病是遗传、内源性和环境因素复杂相互作用的结果，其中免疫系统起着关键作用。因此，免疫系统是许多银屑病治疗方法的主要靶点。该领域的最新进展是所谓的生物制剂，即通过生物工程获得的定制生物分子。本综述总结了目前关于五种已获官方批准用于治疗中度至重度银屑病的专利生物制剂（阿达木单抗、阿法西普、依法利珠单抗、依那西普和英夫利昔单抗）的疗效、安全性和不良反应的可用数据。还讨论了一些关于上述生物制剂未来可能进展的专利申请。
